Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924544 | 0.81 | PKM (0.58) | ALDH1A1POLBKMT2AMEN1PKM | |
| SCHEMBL11835973 | 0.81 | ALDH1A1 (0.52) | CYP2C9ALDH1A1L3MBTL1TP53POLB | |
| SCHEMBL12207380 | 0.80 | CYP2C9 (0.57) | CYP2C9ALDH1A1L3MBTL1POLBKMT2A | |
| SCHEMBL11776237 | 0.79 | CYP2C9 (0.52) | CYP2C9ALDH1A1L3MBTL1TP53POLB | |
| SCHEMBL2970095 | 0.79 | POLB (0.49) | CYP2C9ALDH1A1L3MBTL1TP53POLB | |
| SCHEMBL4776900 | 0.79 | CYP2C9 (0.47) | CYP2C9ALDH1A1L3MBTL1TP53POLB | |
| SCHEMBL2967842 | 0.79 | POLB (0.49) | CYP2C9ALDH1A1L3MBTL1TP53POLB | |
| SCHEMBL2970096 | 0.79 | POLB (0.49) | CYP2C9ALDH1A1L3MBTL1TP53POLB | |
| SCHEMBL3646665 | 0.78 | CYP2C9 (0.55) | CYP2C9ALDH1A1L3MBTL1POLBKMT2A | |
| SCHEMBL13007126 | 0.78 | L3MBTL1 (0.61) | CYP2C9ALDH1A1L3MBTL1TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DE DR. ESTEVE, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIES DE DR. ESTEVE, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| WO-2007128460-A1 | SUBSTITUTED 3 -AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-15 | — | — | WO | disclosed |
| EP-1849781-A1 | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168093-A1 | SUBSTITUTED 3-AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | PAH, HMBS, P4HA1 | CYP2C9 570/4885ALDH1A1 507/4885L3MBTL1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.